Motilal Oswal: Dr. Reddy's Labs Neutral, Rs 1250 target on balanced outlook

• Motilal Oswal maintains a "Neutral" rating on Dr. Reddy's Labs with a target price of Rs 1250.
• Near-term performance of Dr. Reddy's Labs is expected to be impacted by increased g-Revlimid competition.
• Dr. Reddy's Labs is focusing on future growth with promising products like Semaglutide (FY27) and Abatacept (FY28).
• The company aims for double-digit growth in India, EU, Emerging Markets, and PSAI, alongside cost-rationalization.
• Dr. Reddy's Labs has INR28b in cash reserves for potential inorganic growth opportunities.

Why It Matters: Investors get Motilal Oswal's neutral rating and target price for Dr. Reddy's stock.